Skip to main content

Advertisement

SpringerLink
Log in

Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The purpose of this study was to determine whether dynamic susceptibility contrast MR perfusion relative cerebral blood volume (rCBV) correlates with prognosis of World Health Organization (WHO) grade III glial tumors and their different subtypes. Retrospective evaluation of pre-treatment tumor rCBV derived from dynamic susceptibility contrast MR perfusion was performed in 34 patients with histopathologically diagnosed WHO grade III glial tumors (anaplastic astrocytomas (n = 20), oligodendrogliomas (n = 4), and oligoastrocytomas (n = 10)). Progression free survival was correlated with rCBV using Spearman rank analysis. ROC curve analysis was performed to determine the operating point for rCBV in patients with anaplastic astrocytomas dichotomized at the median progression free survival time. For all grade III tumors (n = 34) the mean rCBV was 2.51 with a progression free survival of 705.5 days. The mean rCBV of anaplastic astrocytomas was 2.47 with progression free survival 495.2 days. In contrast, the mean rCBV for oligodendroglial tumors was 2.56 with a progression free survival of 1005.6 days. Although there was no significant correlation between rCBV and progression free survival among all types of grade III gliomas (P = 0.12), among anaplastic astrocytomas there was a significant correlation between pretreatment rCBV and progression free survival with correlation coefficient of −0.51 (P = 0.02). The operating point for rCBV in patients with anaplastic astrocytomas dichotomized at the median progression free survival time (446.5 days) was 2.86 with 78 % accuracy and there was a significant difference between the survival of patients with anaplastic astrocytomas in the dichotomized groups (P = 0.0009). Pre-treatment rCBV may serve as a prognostic imaging biomarker for anaplastic astrocytomas, but not grade III oligodendroglioma tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Kleihues P, Cavenee WK (2000) Pathology and genetics of tumours of the nervous system. IARC, Lyon

    Google Scholar 

  2. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109

    Article  PubMed Central  PubMed  Google Scholar 

  3. Aronen HJ, Gazit IE, Louis DN et al (1994) Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 191:41–51

    CAS  PubMed  Google Scholar 

  4. Leon SP, Folkerth RD, Black P (1996) Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77:362–372

    Article  CAS  PubMed  Google Scholar 

  5. Von Deimling A, Louis DN, von Ammon K et al (1992) Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 52:4277–4279

    Google Scholar 

  6. Curran WJ, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 85:704–710

    Article  PubMed  Google Scholar 

  7. Scott SCB, Scarantino C, Urtasun R et al (1998) Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40:51–55

    Article  CAS  PubMed  Google Scholar 

  8. Bruner JM, Inouye L, Fuller GN, Langford LA (1997) Diagnostic discrepancies and their clinical impact in a neuropathology referral practice. Cancer 79:796–803

    Article  CAS  PubMed  Google Scholar 

  9. Law M, Oh S, Babb JS et al (2006) Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging—prediction of patient clinical response. Radiology 238:658–667

    Article  PubMed  Google Scholar 

  10. Oh J, Henry RG, Pirzkall A et al (2004) Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 19:546–554

    Article  PubMed  Google Scholar 

  11. Pope WB, Sayre J, Perlina A et al (2005) MR imaging correlates of survival in patients with high-grade gliomas. Am J Neuroradiol 26:2466–2474

    PubMed  Google Scholar 

  12. Li Y, Lupo JM, Polley MY et al (2011) Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme. Neuro Oncol 13:546–557

    Article  PubMed Central  PubMed  Google Scholar 

  13. Haselhorst R, Kappos L, Bilecen D et al (2000) Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: application of an extended blood–brain barrier leakage correction. J Magn Reson Imaging 11:495–505

    Article  CAS  PubMed  Google Scholar 

  14. Wetzel SG, Cha S, Johnson G et al (2002) Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 224:797–803

    Article  PubMed  Google Scholar 

  15. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280

    CAS  PubMed  Google Scholar 

  16. Law M, Young RJ, Babb JS et al (2008) Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247:490–498

    Article  PubMed Central  PubMed  Google Scholar 

  17. Stark AM, Nabavi A, Mehdorn HM, Blomer U (2005) Glioblastoma multiforme: report of 267 cases treated at a single institution. Surg Neurol 63:162–169

    Article  PubMed  Google Scholar 

  18. Stupp R, Reni M, Gatta G, Mazza E, Vecht C (2007) Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol 63:72–80

    Article  PubMed  Google Scholar 

  19. Hirai T, Murakami R, Nakamura H et al (2008) Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol 29:1505–1510

    Article  CAS  PubMed  Google Scholar 

  20. Cha S, Tihan T, Crawford F et al (2005) Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. Am J Neuroradiol 26:266–273

    PubMed  Google Scholar 

  21. Lev MH, Ozsunar Y, Henson JW et al (2004) Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendroglimoas. AJNR Am J Neuroradiol 25:214–221

    PubMed  Google Scholar 

  22. Bisdas S, Kirkpatrick M, Giglio P et al (2009) Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease? AJNR Am J Neuroradiol 30:681–688

    Article  CAS  PubMed  Google Scholar 

  23. Schiffer D, Dutto A, Cavalla P et al (1997) Prognostic factors in oligodendroglioma. Can J Neurol Sci 24:313–319

    CAS  PubMed  Google Scholar 

  24. Mork SJ, Halvorsen TB, Lindegaard KF, Eide GE (1986) Oligodendroglioma: histologic evaluation and prognosis. J Neuropathol Exp Neurol 45:65–78

    Article  CAS  PubMed  Google Scholar 

  25. Engelhard HH, Stelea A, Mundt A (2003) Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol 60:443–456

    Article  PubMed  Google Scholar 

  26. Whitmore RG et al (2007) Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg 107:600–609

    Article  CAS  PubMed  Google Scholar 

  27. Christov C, Adle-Biassette H, Le Guerinel C et al (1998) Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas. Neuropathol Appl Neurobiol 24:29–35

    Article  CAS  PubMed  Google Scholar 

  28. Lafuente JV, Adán B, Alkiza K, Garibi JM, Rossi M, Cruz-Sánchez FF (1999) Expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor-beta (PDGFR-beta) in human gliomas. J Mol Neurosci 13:177–185

    Article  CAS  PubMed  Google Scholar 

  29. Pietsch T, Valter MM, Wolf HK et al (1997) Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 93:109–117

    Article  CAS  PubMed  Google Scholar 

  30. Maia AC Jr, Malheiros SM, da Rocha AJ et al (2005) MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 26:777–783

    PubMed  Google Scholar 

  31. Netto GC, Bleil CB, Hilbig A et al (2008) Immunohistochemical evaluation of the microvascular density through the expression of TGF-b (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas. Neuropathology 28:17–23

    Article  PubMed  Google Scholar 

  32. Boxerman J, Schmainda KM, Weisskoff RM (2006) Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade whereas uncorrected maps do not. AJNR Am J Neuroradiol 27:859–867

    CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None of the authors have conflicts of interests or any relevant disclosures.

Author information

Authors and Affiliations

  1. Department of Imaging Sciences, University of Rochester School of Medicine & Dentistry, Rochester, NY, USA

    Rajiv Mangla & Sven Ekholm

  2. Department of Radiology, University of Chicago Medical Center, 5841 S Maryland Avenue, Chicago, IL, 60637, USA

    Daniel Thomas Ginat

  3. Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Shervin Kamalian

  4. Department of Radiation Oncology, University of Rochester School of Medicine & Dentistry, Rochester, NY, USA

    Michael T. Milano

  5. Department of Pediatric Oncology, University of Rochester School of Medicine & Dentistry, Rochester, NY, USA

    David N. Korones

  6. Department of Neurosurgery, University of Rochester School of Medicine & Dentistry, Rochester, NY, USA

    Kevin A. Walter

Authors
  1. Rajiv Mangla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Thomas Ginat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shervin Kamalian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael T. Milano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David N. Korones
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kevin A. Walter
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sven Ekholm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Thomas Ginat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mangla, R., Ginat, D.T., Kamalian, S. et al. Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes. J Neurooncol 116, 325–331 (2014). https://doi.org/10.1007/s11060-013-1298-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-013-1298-9

Keywords

Search

Navigation